Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2B Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Namodenoson in the Treatment of Non-Alcoholic Steatohepatitis (NASH)

NCT04697810 is registered in ClinicalTrials.gov with Can-Fite BioPharma as lead sponsor.

NCT NCT04697810
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04697810 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2B Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Namodenoson in the Treatment of Non-Alcoholic Steatohepatitis (NASH)
Lead sponsor
Can-Fite BioPharma
Phase
Phase 2
Overall status
Unknown status
Start date
December 10, 2021
Completion date
October 15, 2025
Enrollment
114 (estimated)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

nash - nonalcoholic steatohepatitis